Generic Imatinib Therapy Among Jordanians: An Observational Assessment of Efficacy and Safety in Routine Clinical Practice Abdalla Awidi, Salah Abbasi,

Slides:

Advertisements

Similar presentations

Incidence and Risk of Cardiac Events in Patients With Previously Treated Multiple Myeloma Versus Matched Patients Without Multiple Myeloma: An Observational,

Advertisements

Rationale and design of a randomized clinical trial to assess the safety and efficacy of frequent optimization of cardiac resynchronization therapy: The.

Large-Cell Transformation of Mycosis Fungoides Occurring at the Site of Previously Treated Cutaneous B-Cell Lymphoma Jennifer L. Herrmann, Naveed Sami

Ten-day bismuth-containing quadruple therapy is effective as first-line therapy for Helicobacter pylori–related chronic gastritis: a prospective randomized.

The Prognostic Significance of Elevated Levels of Serum Ferritin Before Chemotherapy in Patients With Non-Hodgkin Lymphoma Kyung Ah Yoh, Ho Sup Lee,

Resistance in the land of molecular cancer therapeutics

Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase: Identification and Management Jorge E. Cortes, Carlos.

Monitoring Milestones in Patients With Chronic Myeloid Leukemia

Patient-Reported Outcomes Data From REVEAL at the Time of Enrollment (Baseline): A Prospective Observational Study of Patients With Polycythemia Vera.

Yuji Nakamoto Clinical Lymphoma, Myeloma and Leukemia

Mortality and Vascular Events Among Elderly Patients With Chronic Myeloid Leukemia: A Retrospective Analysis of Linked SEER-Medicare Data Kathleen Lang,

Incidence and Risk of Cardiac Events in Patients With Previously Treated Multiple Myeloma Versus Matched Patients Without Multiple Myeloma: An Observational,

The Epidemiology and Clinical Associations of Stroke in Patients With Acute Myeloid Leukemia: A Review of 10,972 Admissions From the 2012 National Inpatient.

Efficacy of Standard Dose R-CHOP Alternating With R-HDAC Followed by Autologous Hematopoietic Cell Transplantation as Initial Therapy of Mantle Cell Lymphoma,

Ten-day bismuth-containing quadruple therapy is effective as first-line therapy for Helicobacter pylori–related chronic gastritis: a prospective randomized.

Residual Cancer Lymphocytes in Patients With Chronic Lymphocytic Leukemia After Therapy Show Increased Expression of Surface Antigen CD52 Detected Using.

Treatment With JAK Inhibitors in Myelofibrosis Patients Nullifies the Prognostic Impact of Unfavorable Cytogenetics Vincent T. Ma, Philip S. Boonstra,

Prolonged Duration of Therapy Is Associated With Improved Survival in Patients Treated for Relapsed/Refractory Multiple Myeloma in Routine Clinical Care.

Limited Utility of Surveillance Imaging for Detecting Disease Relapse in Patients With Non-Hodgkin Lymphoma in First Complete Remission Quoc Truong,

Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma.

Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab.

Consolidative Radiotherapy to Residual Masses After Chemotherapy Is Associated With Improved Outcome in Diffuse Large B-Cell Lymphoma. A Retrospective,

A Comparison of Clofarabine-based (GCLAC) and Cladribine-based (CLAG) Salvage Chemotherapy for Relapsed/Refractory AML Benyam Muluneh, Kaitlyn Buhlinger,

Subepithelial Corneal Immunoglobulin Deposition as a Manifestation of Multiple Myeloma: A Case Report and Literature Review Trent P. Wang, Steven G.

Ibrutinib Dose Adherence and Therapeutic Efficacy in Non-Hodgkin Lymphoma: A Single-Center Experience AnnaLynn M. Williams, Andrea M. Baran, Carla Casulo,

Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence In Situ Hybridization/Cytogenetics: A Real-world.

Effects of Ruxolitinib Treatment on Metabolic and Nutritional Parameters in Patients With Myelofibrosis From COMFORT-I Ruben A. Mesa, Srdan Verstovsek,

Systematic Literature Review of Treatment Options and Clinical Outcomes for Patients With Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic.

Interim Functional Imaging Is an Independent Predictor of Progression-free Survival in Advanced Classical Hodgkin Lymphoma – A Real-world Analysis Moussab.

Health-Related Quality of Life of Patients With Multiple Myeloma Treated in Routine Clinical Practice in France Nicolas Despiégel, Chantal Touboul, Alain.

Efficacy and Toxicity of Idarubicin Versus High-dose Daunorubicin for Induction Chemotherapy in Adult Acute Myeloid Leukemia: A Systematic Review and.

Elotuzumab in Combination with Lenalidomide and Dexamethasone for Treatment- resistant Immunoglobulin Light Chain Amyloidosis With Multiple Myeloma Shumaila.

Volume 26, Issue 2, Pages (February 2018)

Genetic Mutations in B-Acute Lymphoblastic Leukemia Among African American and European American Children Amit Reddy, Ingrid Espinoza, Dana Cole, Jason.

An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma John M. Burke,

Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle.

Vertebral Fracture Risk of Multiple Myeloma Assessed by a CT-based Finite Element and Trabecular Structure Analysis Miyuki Takasu, Yoko Kaichi, Kazuo.

Hemophagocytic Lymphohistiocytosis in a Patient With Multiple Myeloma

Safety and Preliminary Efficacy of Vorinostat With R-EPOCH in High-risk HIV- associated Non-Hodgkin's Lymphoma (AMC-075) Juan C. Ramos, Joseph A. Sparano,

Blood Transfusion Management and Transfusion-Related Outcomes in Daratumumab- Treated Patients With Relapsed or Refractory Multiple Myeloma Ajai Chari,

ZOHé: A Prospective Study of the Use of Biosimilar Filgrastim Zarzio in Clinical Practice in Patients Treated With Chemotherapy for Lymphoid Malignancies

Pradnya Chopade, Luke P. Akard Clinical Lymphoma, Myeloma and Leukemia

Clinical and Disease Characteristics From REVEAL at Time of Enrollment (Baseline): Prospective Observational Study of Patients With Polycythemia Vera.

Clinical Lymphoma, Myeloma and Leukemia

Single-Agent Liposomal All-Trans-Retinoic Acid as Initial Therapy for Acute Promyelocytic Leukemia: 13-Year Follow-Up Data Preetesh Jain, Hagop Kantarjian,

Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I Carole B. Miller, Rami S. Komrokji, Ruben A. Mesa,

Clinical Efficacy of Romidepsin in Tumor Stage and Folliculotropic Mycosis Fungoides Francine Foss, Madeleine Duvic, Adam Lerner, Joel Waksman, Sean Whittaker

A Post Hoc Sensitivity Analysis of Survival Probabilities in a Multinational Phase III Trial of Decitabine in Older Patients With Newly Diagnosed Acute.

Kamal V. Patel, Rishi M. Goel, Terry Wong

Sorafenib As Monotherapy or in Association With Cytarabine and Clofarabine for the Treatment of Relapsed/Refractory FLT3 ITD-Positive Advanced Acute Myeloid.

Accelerating Patients’ Access to Advanced Therapies in the EU

Madeliene Parrott, Simon Rule, Michael Kelleher, Jayne Wilson

Rituximab-Based Chemoimmunotherapy Prolongs Survival of Patients With Chronic Lymphocytic Leukemia Independently of the Time of Administration Julio.

Predictive and Prognostic Markers in Adults With Acute Myeloid Leukemia: A Single- Institution Experience Bolanle Gbadamosi, Daniel Ezekwudo, Sanjog Bastola,

Comparing two low-energy diets for the treatment of knee osteoarthritis symptoms in obese patients: a pragmatic randomized clinical trial B.F. Riecke,

Effectiveness and Safety of Therapeutic Regimens for Elderly Patients With Acute Myeloid Leukemia: A Systematic Literature Review Jill A. Bell, Aaron.

Modified VR-CAP, Alternating With Rituximab and High-dose Cytarabine: An Effective Pre-transplant Induction Regimen for Mantle Cell Lymphoma Stephen.

Large-Cell Transformation of Mycosis Fungoides Occurring at the Site of Previously Treated Cutaneous B-Cell Lymphoma Jennifer L. Herrmann, Naveed Sami

Challenges in Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN)

Comparison of Frequency and Sensitivity of BCR-ABL1 Kinase Domain Mutations in Asian and White Patients With Imatinib-resistant Chronic–Phase Chronic.

Phase II Study of Vincristine Sulfate Liposome Injection (Marqibo) and Rituximab for Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma.

In This Issue Molecular Therapy Volume 16, Issue 4, (April 2008)

Evaluating the Impact of a Switch to Nilotinib on Imatinib-Related Chronic Low-Grade Adverse Events in Patients With CML-CP: The ENRICH Study Jorge E.

Residual Cancer Lymphocytes in Patients With Chronic Lymphocytic Leukemia After Therapy Show Increased Expression of Surface Antigen CD52 Detected Using.

Clinical Lymphoma, Myeloma and Leukemia

Volume 139, Issue 6, Pages e1 (December 2010)

Pure Erythroid Leukemia Presenting in a HIV-Positive Patient

Suboptimal Response to or Failure of Imatinib Treatment for Chronic Myeloid Leukemia: What Is the Optimal Strategy? Elias Jabbour, MD, Jorge E. Cortes,

Autologous Stem Cell Transplantation for POEMS Syndrome

Ruxolitinib for Myelofibrosis–An Update of Its Clinical Effects

Presentation transcript:

Generic Imatinib Therapy Among Jordanians: An Observational Assessment of Efficacy and Safety in Routine Clinical Practice Abdalla Awidi, Salah Abbasi, Kamal Alrabi, Khalid A. Kheirallah Clinical Lymphoma, Myeloma and Leukemia Volume 17, Issue 12, Pages e55-e61 (December 2017) DOI: 10.1016/j.clml.2017.08.001 Copyright © 2017 The Authors Terms and Conditions

Figure 1 Flowchart of Patients Clinical Lymphoma, Myeloma and Leukemia 2017 17, e55-e61DOI: (10.1016/j.clml.2017.08.001) Copyright © 2017 The Authors Terms and Conditions

Figure 2 Response in the First-line Patients at Month 12. Ten (30% of 33) Patients Had No Efficacy Data at Month 12, and Therefore Were Excluded From the Evaluable Patients and Included in the ITT Population Abbreviations: CCyR = complete cytogenetic response; ITT = intention-to-treat; MMR = major molecular response; PCyR = partial cytogenic response. Clinical Lymphoma, Myeloma and Leukemia 2017 17, e55-e61DOI: (10.1016/j.clml.2017.08.001) Copyright © 2017 The Authors Terms and Conditions

Figure 3 Response in Switched Patients at Month 12. Three (5% of 58) Patients Had No Efficacy Data at Month 12, and Therefore Were Excluded From the Evaluable Patients and Included in the ITT Population Abbreviations: CCyR = complete cytogenetic response; ITT = intention-to-treat; MMR = major molecular response; PCyR = partial cytogenic response. Clinical Lymphoma, Myeloma and Leukemia 2017 17, e55-e61DOI: (10.1016/j.clml.2017.08.001) Copyright © 2017 The Authors Terms and Conditions